"We Envision Growth Strategies Most Suited
to Your Business"
November 08, 2019 | Healthcare
The global plasma fractionation market size is anticipated to reach USD 38.65 Billion by 2026. Increasing number of patients with congenital disorders, along with rising research and development (R&D) activities, will drive the market. Fortune Business Insights has published a report, titled “Plasma Fractionation Market Size, Share & Industry Analysis, By Product Type (Albumin, Immunoglobulin (Intravenous Immunoglobulin and Subcutaneous Immunoglobulin), Coagulation Factors (Factor IX, Factor VIII, Prothrombin Complex Concentrates, Fibrinogen concentrates and Others), Protease Inhibitors and Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology and Others), By End User (Hospitals & Clinics, Clinical Research Laboratories and Others (Academic Institutes, etc.)) and Geography Forecast, 2019-2026.”
As per the report, the market was worth USD 24.07 Billion in 2018. Furthermore, it is likely to exhibit a CAGR of 6.2% during the projected horizon, 2019-2016. One of the primary factors boosting the market is the presence of well-established blood plasma fractionation facilities across the world. Several biotechnology companies are planning to develop improvised and advanced facilities to produce blood plasma proteins such as immunoglobulins, albumin, clotting factors among others.
The process of separating different plasma components is called plasma fractionation. This process is used to diagnose and treat life-threating diseases that are caused by infections, immunological disorders, and trauma. Furthermore, plasma fractionation process is used in the treatment of protein deficiency in several healthcare applications.
This process plays a significant role in separating therapeutic proteins in the human blood. Other proteins such as thrombin, fibrinogen, and prothrombin complex also play a crucial role in disease therapeutics. Plasma fractionated products help in the treatment of congenital metabolic and immunological disorders. Spurred by this factor, the plasma fractionation industry is expected to expand in the forthcoming years.
Immunoglobulins to Hold 47.9% Share
As per the current plasma fractionation market trends, coagulation and immunoglobulin products are likely to emerge dominant in the market. As per the report, immunoglobulins covered a share of 47.9% in 2018 and is likely to lead the market. Coagulation products are the second-most leading segment and a cover a higher part of the plasma fractionation market share. Apart from these products, protease inhibitors are expected to rise at a higher CAGR on account of their positive results for the prevention of several viral infections. In addition to this, the prevalence of viral outbursts is increasing across the globe.
This, as a result, will stimulate growth in the protease inhibitors segment in the years to come. Moreover, these products help in the detection of HIV, which will further increase their adoption in the forecast years. The demand for albumin, protease inhibitors, and other products is expected to increase as these are used to treat people suffering from life-threating disorders.
Increasing Usage of Plasma Proteins to Fuel Demand for Immunology and Neurology Applications
Among different applications, immunology and neurology is expected to rise at moderately higher CAGR in the forecast years. The growth is attributable to the rising use of plasma proteins which include coagulation factors for R&D of immunology and neurology, immunoglobulins, and treatment procedures. Immunoglobulins are used widely across the world as they help in the detection and prevention of several complex disorders such as myasthenia gravis, Alzheimer’s disease, among others. Other applications such as hematology, pulmonology, and critical care are anticipated to expand at a higher CAGR in the foreseeable future.
Among end-users, hospitals are expected to have a dominant share in the market owing to the rising demand for plasma proteins. These proteins help in the diagnosis and offer high-quality treatment to patients suffering from several chronic diseases. In addition to this, increasing number of in-patients is propelling growth in the hospitals segment. Apart from hospitals, clinical research laboratories are also likely to exhibit higher CAGR by 2026. This is ascribable to the increasing availability of plasma proteins and other resources with an aim to carry scientific experiments.
Biopharma to Launch a State-of-art Plasma Fractionation Plant in Ukraine
Octapharma, Kedrion S.p.A., Baxter, Shire, Biotest AG, and LFB are some of the players leading in the market. Players such as CSL and Grifols cover the highest share in the global market owing to their continuous investments in R&D activities. Companies are putting efforts to expand their geographical presence and stay ahead of competition.
For instance, Biopharma announced the launch of a new state-of-art plasma fractionation plant in Ukraine in September 2019. This is the only innovative plant in Eastern Europe with advanced plasma fractionation technology. It processes the plasma part of human blood to extract life-saving drugs. Such advancements are expected to drive the market in Europe. North America is expected to lead the global plasma fractionation market in the forecast years. Highly developed infrastructure and favorable government policies are favoring the market growth in this region. Rising adoption of plasma fractionation systems in China and India is likely to exhibit moderate growth in the market in Asia Pacific.
Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614
The global plasma fractionation market can be segmented as follows:
Value (USD Billion)
By Product Type
By End User